Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
maytansine/leukemia
Länken sparas på Urklipp
Sida 1 från 23 resultat
Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Maytansine is a new drug undergoing clinical investigation. It has functional similarities to vincristine. Maytansine and vincristine were given to CDF1 mice with P388 leukemic ascites, and the cytokinetic response of the tumor cells was analyzed with a flow microfluorometer; mithramycin was used as
Maytansine in refractory childhood acute lymphocytic leukemia: a Pediatric Oncology Group study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Initial studies on maytansine-induced metaphase arrest in L1210 murine leukemia cells.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Stathmokinetic and therapeutic effects of maytansine in mice bearing P388 and L1210 leukemias.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
AVE9633 is a new immunoconjugate comprising a humanized monoclonal antibody, anti-CD33 antigen, linked through a disulfide bond to the maytansine derivative DM4, a cytotoxic agent and potent tubulin inhibitor. It is undergoing a phase I clinical trial. Chemoresistance to anti-mitotic
Establishment and properties of vincristine-resistant human myelogenous leukemia K562.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A vincristine (VCR)-resistant subline of human K562 myelogenous leukemia was established in vitro, and several clones with different susceptibilities to VCR were isolated by the limiting dilution technique. The most resistant clone (H-1) had a 17-fold greater resistance to VCR when compared to the
Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Bone marrow cells and peripheral blood mononuclear cells obtained from both acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients contain upregulated levels of cell surface antigen CD33 compared with healthy controls. This difference enables the use of humanized anti-CD33 antibody
Increase in the chemically-induced differentiation of human leukemia cell lines by tubulin disruptors.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The effect of various structural/functional tubulin disruptors (including colchicine-type disruptors, vinblastine, rhizoxin, maytansine, peptide-type disruptors, and taxol) on the chemically induced differentiation of human leukemia cell lines (HL-60 and K562) was examined. As
Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
We examined the cytotoxic effect of maytanprine isolated from the methanol extract of Maytenus diversifolia on human leukemia K562 cells using a flow cytometer and compared its cytotoxicity with that of maytansine, a potent cytotoxic maytansinoid. Maytanprine at concentrations of 0.03 nM or more (up
Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
During phase I trials with maytansine some activity against lymphoma and lymphocytic leukemia was noted. Therefore, a phase II trial of maytansine in patients with advanced lymphomas refractory to conventional chemotherapy was begun. There were three partial responders (10%) among 31 patients
Initial clinical trials of maytansine, an antitumor plant alkaloid.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
We have conducted a phase I clinical trial of maytansine, a plant alkaloid with potent tubulin-binding activity. For evaluation of toxicity, the schedule of drug administration consisted of a single iv infusion given every 3 weeks. Dose-limiting toxicity was observed at 2 mg/m2, and was manifested
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Acute myeloid leukemia (AML) is the most common leukemia among adults and is associated with a poor prognosis, especially in patients with adverse prognostic factors, older age, or relapsed disease. The last decade has seen a surge in successful immune-based therapies in various solid tumors;
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The efficacy of anti-CD33 immunoconjugates had been previously demonstrated for gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by ImmunoGen Inc. Phase I trials of AVE9633 were performed in patients with AML to evaluate tolerability, pharmacokinetics and pharmacodynamics.
Derivatives of 5,6-diphenylpyridazin-3-one: synthetic antimitotic agents which interact with plant and mammalian tubulin at a new drug-binding site.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A series of derivatives of 5,6-diphenylpyridazin-3-one (DPP) was examined for interactions with calf brain tubulin following the demonstration that many members of the class caused significant mitotic effects in intact animals, while others had activity against murine P388 leukemia. In L1210 cells
Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The effects of microtubule inhibitors on cellular accumulation of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidine-beta-D-glu copyranoside) (VP-16) and subsequent epipodophyllotoxin-induced DNA single-strand breaks were investigated in human leukemia K562 cells. At concentrations of 0.05-20 microM,
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
